Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists
Warren T. Yacawych, Yi Wang, Guoxiang Zhou, Shad Hassan, Cagri Bodur, Elisabeth Walters, John G. Santinga, Frederike Sass, Martin deVaux, Stace Kernodle, Iris Wu, Jenny M. Brown, Dylan Belmont-Rausch, Alan C. Rupp, Abigail J. Tomlinson, Zitian Lin, Emma VanTongeren, Anna Secher, Kirsten Raun, Tune H. Pers, Randy J. Seeley, Martin G. Myers Jr., Weiwei Qiu
Warren T. Yacawych, Yi Wang, Guoxiang Zhou, Shad Hassan, Cagri Bodur, Elisabeth Walters, John G. Santinga, Frederike Sass, Martin deVaux, Stace Kernodle, Iris Wu, Jenny M. Brown, Dylan Belmont-Rausch, Alan C. Rupp, Abigail J. Tomlinson, Zitian Lin, Emma VanTongeren, Anna Secher, Kirsten Raun, Tune H. Pers, Randy J. Seeley, Martin G. Myers Jr., Weiwei Qiu
View: Text | PDF
Research Article Metabolism Neuroscience

A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists

  • Text
  • PDF
Abstract

Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP1RAs) effectively reduce feeding to treat obesity, although nausea and other aversive side effects of these drugs can limit their use. Brainstem circuits that promote satiation and mediate the physiological control of body weight can be distinguished from those that cause aversion. It remains unclear, however, whether brainstem Glp1r neurons contribute to the normal regulation of energy balance and whether GLP1RAs control appetite via circuits distinct from those that mediate aversive responses. Here, we silenced Glp1r neurons in the nucleus of the solitary tract (NTS) or area postrema (AP) (NTSGlp1r or APGlp1r neurons, respectively) or restored their GLP1R signaling on an otherwise GLP1R-deficient background to determine physiological and pharmacological roles for each neuron population. Although NTSGlp1r neurons contributed to the normal restraint of food intake and body weight, they failed to mediate GLP1RA-dependent weight loss. In contrast, while we detected no role for APGlp1r neurons in physiological feeding, they mediated both the weight-lowering and aversive effects of GLP1RAs. Therefore, while nonaversive NTSGlp1r neurons controlled physiologic satiation they did not contribute to weight loss during GLP1RA treatment. Rather, APGlp1r neurons mediated both the weight-lowering and aversive effects of GLP1RAs, preventing the separation of their nauseating and weight-loss effects at a circuit level.

Authors

Warren T. Yacawych, Yi Wang, Guoxiang Zhou, Shad Hassan, Cagri Bodur, Elisabeth Walters, John G. Santinga, Frederike Sass, Martin deVaux, Stace Kernodle, Iris Wu, Jenny M. Brown, Dylan Belmont-Rausch, Alan C. Rupp, Abigail J. Tomlinson, Zitian Lin, Emma VanTongeren, Anna Secher, Kirsten Raun, Tune H. Pers, Randy J. Seeley, Martin G. Myers Jr., Weiwei Qiu

×

Figure 5

Overexpression of hGLP1R in NTSGlp1r neurons does not alter the long-term response to GLP1Ras.

Options: View larger image (or click on image) Download as PowerPoint
Overexpression of hGLP1R in NTSGlp1r neurons does not alter the long-ter...
(A) Example DVC image of hGLP1R IR in NTSOX-hGLP1R mice. (B) Example image of hGLP1R IR in Glp1rWT mice. Scale bars: 100 μm. (C and D) Food intake over a 24-hour period in Glp1rWT (n = 7) and NTSOX-hGLP1R mice (n = 10) treated with Sema (C) or AZD0186 (D). (E–J) Glp1rWT (n = 7) and NTSOX-hGLP1R mice (n = 10) were treated once daily with Sema (E–G) or twice daily with AZD0186 (H–J). Shown for the Sema study are daily food intake values normalized to vehicle baseline days (E), cumulative food intake throughout the treatment period (F), and daily body weight normalized to vehicle baseline values (G). Shown for the study with AZD0186 are daily food intake values normalized to vehicle baseline days (H), cumulative food intake throughout the treatment period (I), and daily body weight normalized to vehicle baseline values (J). Total body weight loss following Sema (K) or AZD0186 (L) treatment in Glp1rWT (n = 7) and NTSOX-hGlp1r mice (n = 10). Pink circles indicate data for female mice; brown circles indicate data for male mice. (M and N) Example images of FOS IR (green) in the DVC for AZD0186 in Glp1rWT (M) or NTSOX-hGLP1R (N) mice, with digital zoom insets of the NTS (Original magnification, ×10). (O) Quantification of FOS IR in the NTS from the samples (n = 4 each) represented in M and N. Two-way ANOVA with Tukey’s multiple comparisons for C, D, and O; repeated-measures, 2-way ANOVA with Tukey’s multiple comparisons for E–J; unpaired, 2-tailed t test with Welch’s correction for K and L. NS = P < 0.05; F: NS = P > 0.05; **P < 0.01 and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts